Injectafer contraindications
Webb25 mars 2024 · The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports with Injectafer: urticaria, dyspnea, pruritis, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope. WebbInjectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components. WARNINGS AND PRECAUTIONS Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting.
Injectafer contraindications
Did you know?
WebbInjectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components. WARNINGS AND PRECAUTIONS Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting.
WebbFor patients weighing less than 50 kg (110 lb): Give Injectafer in two doses separated by at least 7 days. Give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course. The dosage of Injectafer is expressed in mg of elemental iron. Each mL of Injectafer contains 50 mg of elemental iron. Webb1 feb. 2024 · When administering Injectafer 750 mg as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. For Injectafer 1,000 mg, administer as a slow intravenous push over 15 minutes. Avoid extravasation of Injectafer since brown discoloration of the extravasation site may be long lasting. Monitor for extravasation.
WebbInjectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components. Warnings and Precautions Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. Webb8 jan. 2024 · Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful ... (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%. In patients with iron deficiency, the red cell uptake ranged from 91% to 99%. In patients with renal anemia, the red ...
WebbCONTRAINDICATIONS / PRECAUTIONS Hemochromatosis, hemoglobinopathy, hemosiderosis Do not administer ferric carboxymaltose to patients with evidence of iron overload (e.g., patients with hemochromatosis). Unnecessary or prolonged administration of iron may lead to iron overload and consequently the possibility of exogenous …
Webbadministered as two doses of 750 mg each separated by at least seven days.1 Injectafer has been studied in more than 40 clinical trials that included over 8,800 patients worldwide.3 Injectafer has been approved in 83 countries since initial European Union approval in 20074 and is the most extensively studied intravenous iron.5. About … openingsscherm fotoWebb4 CONTRAINDICATIONS . Injectafer is contraindicated in patients with a history of hypersensitivity to Injectafer or any of its components [see Warnings and Precautions (5.1) ]. 5 WARNINGS AND... ip04-12t-r2aWebbContraindications Hypersensitivity to Injectafer or any of its components. Warnings Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. openingsscherm computerWebb27 nov. 2024 · Injectafer (active ingredient – ferric carboxymaltose) is an iron replacement product that is used to treat iron deficiency anemia. Venofer (active ingredient – iron sucrose) is a form of mineral iron that is used to treat iron deficiency anemia in people with kidney disease. This medication is not for treating other forms of anemia not ... openingsscherm windows 11Webb1 juli 2012 · CONTRAINDICATIONS Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components. Please see Important Safety Information on page 3 and click here for full Prescribing Information for Injectafer. Insurers may require a prior authorization (PA) as part of a claim submission. ip 07 goinfraWebb6 maj 2024 · INDICATIONS Injectafer ® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had... ip04-18t-r2a datasheetWebb3. Contraindications The use of these intravenous (IV) iron preparations is contra-indicated in cases of: Known hypersensitivity to either product or any of its components Anaemia not attributable to iron deficiency Iron overload or disturbances in utilisation of iron Caution should be exercised in: openingsscherm windows